SUNNYVALE, Calif., July 14, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its CyberKnife and TomoTherapy Systems continue to set the standard for overall user satisfaction. The Accuray systems received the highest composite overall user satisfaction rating among radiation treatment delivery systems in the U.S., according to the Q2 2016 MD Buyline Market Intelligence Briefing™. The most recent ratings trend also shows Accuray has achieved the highest ratings among industry peers over the past three years.

In rating the Accuray systems, MD Buyline reports the company obtained the highest scores in a majority of categories measured including system performance, system reliability, service response time and service repair quality. CyberKnife System users also 'highly recommend' the InCise™ Multileaf Collimator (MLC) noting 'it makes the treatment time much more efficient.' CyberKnife and TomoTherapy System users continued to 'praise the high level of reliability afforded by Accuray systems.'

'The independent MD Buyline report is further evidence we are succeeding with our strategy to drive innovative cancer care with a clear focus on customer satisfaction,' said Joshua H. Levine, president and CEO of Accuray. 'The feedback continues to validate the TomoTherapy System's functionality as a workhorse radiation oncology device while also highlighting the expanded efficiency of our next generation CyberKnife System equipped with an MLC. Our strong overall user satisfaction ratings are a major factor behind our growth in the marketplace.'

For more information on the CyberKnife and TomoTherapy Systems visit www.accuray.com.

MD Buyline, an independent market intelligence organization for the healthcare industry, measures linear accelerator user satisfaction based on evaluations by more than 3,300 hospitals in its member network that use the product every day. Respondents rate how satisfied they are with products from Accuray, Elekta and Varian, using key metrics listed above along with installation and implementation, applications training, and service repair quality. (MD Buyline User Satisfaction Ratings, MD Buyline Market Intelligence Briefing™ Q2 2016) © 2016 MD Buyline, All Rights Reserved. Used with Permission July 13, 2016.

About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to future growth, market success, adoption of our new products and services, benefits of our technologies, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading 'Risk Factors' in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015, February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Logo - http://photos.prnewswire.com/prnh/20160108/320376LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-products-continue-to-receive-highest-composite-user-satisfaction-ratings-in-latest-md-buyline-report-300298614.html

SOURCE Accuray Incorporated

Accuray Incorporated published this content on 23 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 July 2016 16:28:01 UTC.

Original documenthttp://investors.accuray.com/phoenix.zhtml?c=177244&p=irol-newsArticle&ID=2187588

Public permalinkhttp://www.publicnow.com/view/3609E1051C81174437F764AF2CCEEC0346AB440C